Following FDA 510(k) clearance in February 2026, DermaForm™ is now being introduced to the US market by StimLabs, Geistlich's exclusive wound care partner in the country. 

DermaForm™ is a particulate collagen product designed for use in chronic and acute wounds. Its flexible format allows healthcare professionals to apply it to wounds of different shapes and sizes, including complex and irregular wound areas. 

David Wemans, VP Regenerative Technologies at Geistlich, commented, “DermaForm is the result of Geistlich’s pioneering spirit and deep scientific expertise in collagen engineering applied specifically to the unmet needs of complex wound management. The product is a combination of deliberate design choices aimed at providing clinicians with a unique product that addresses an unmet clinical need. We are confident that clinicians will see meaningful outcomes with DermaForm, and we are proud to bring it to U.S. patients through our partnership with StimLabs.” 

Building on a successful partnership 

Geistlich and StimLabs began their collaboration in 2024 with the introduction of Derma-Gide®, an advanced wound matrix. The commercial launch of DermaForm™ represents another milestone in this growing partnership, combining Geistlich's expertise in regenerative biomaterials with StimLabs' experience in the US wound care market. 

The launch also reflects Geistlich's ambition to make its regenerative technologies accessible to more healthcare professionals and patients through strategic partnerships. 

Read more about the product and the partnership.